Cargando…
Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
To evaluate early-stage prostate cancer (PCa) radiotherapy treatment patterns and outcomes among Ghanaian men (GM) compared with US men (USM). MATERIALS AND METHODS: This retrospective study consists of 987 National Comprehensive Cancer Network low risk, favorable intermediate risk, and unfavorable...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887629/ https://www.ncbi.nlm.nih.gov/pubmed/31584456 http://dx.doi.org/10.1097/COC.0000000000000589 |
_version_ | 1783475060043939840 |
---|---|
author | Asamoah, Francis A. Yarney, Joel Awasthi, Shivanshu Vanderpuye, Verna Dadzie, Mary A. Fink, Angelina Naghavi, Arash O. Abrahams, Afua Mensah, James E. Sasu, Evans Tagoe, Samuel N. Dhillon, Jasreman Johnstone, Peter A.S. Yamoah, Kosj |
author_facet | Asamoah, Francis A. Yarney, Joel Awasthi, Shivanshu Vanderpuye, Verna Dadzie, Mary A. Fink, Angelina Naghavi, Arash O. Abrahams, Afua Mensah, James E. Sasu, Evans Tagoe, Samuel N. Dhillon, Jasreman Johnstone, Peter A.S. Yamoah, Kosj |
author_sort | Asamoah, Francis A. |
collection | PubMed |
description | To evaluate early-stage prostate cancer (PCa) radiotherapy treatment patterns and outcomes among Ghanaian men (GM) compared with US men (USM). MATERIALS AND METHODS: This retrospective study consists of 987 National Comprehensive Cancer Network low risk, favorable intermediate risk, and unfavorable intermediate risk PCa patient subgroups; GM (173) and USM (814). Differences in baseline covariates and clinical characteristics between GM and USM were analyzed using χ(2) and Mann-Whitney test while Cox Proportional Hazards model was used to assess freedom from biochemical failure differences between the study groups. RESULTS: Median follow-up for this study was 40 months. GM were diagnosed at a younger median age (64 vs. 68 y, P<0.001) with heavier unfavorable intermediate risk disease burden (32.4% vs. 19.2%) compared with USM. Significant differences were identified in median external beam radiotherapy dose (72.4 vs. 78 Gy, P<0.001); brachytherapy utilization (49.7% vs. 80.6%, P<0.001) and androgen deprivation therapy for intermediate risk disease (48.4% vs. 21.0%, P<0.001) between GM and USM, respectively. GM with low risk and favorable intermediate risk PCa were at increased risk of biochemical recurrence compared with USM with adjusted hazard ratio: 5.15 (1.27 to 20.7), P=0.02 and 4.64 (1.20 to 17.92), P=0.02, respectively. CONCLUSIONS: Compared with USM, GM with low and favorable intermediate risk PCa may experience less durable disease control following standard treatment recommendations. Results suggest differences in radiation treatment and possible inherent differences between the 2 populations. This data will aid in developing research strategies to improve treatment outcomes in GM. |
format | Online Article Text |
id | pubmed-6887629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-68876292020-01-22 Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study Asamoah, Francis A. Yarney, Joel Awasthi, Shivanshu Vanderpuye, Verna Dadzie, Mary A. Fink, Angelina Naghavi, Arash O. Abrahams, Afua Mensah, James E. Sasu, Evans Tagoe, Samuel N. Dhillon, Jasreman Johnstone, Peter A.S. Yamoah, Kosj Am J Clin Oncol Original Articles: Genitourinary To evaluate early-stage prostate cancer (PCa) radiotherapy treatment patterns and outcomes among Ghanaian men (GM) compared with US men (USM). MATERIALS AND METHODS: This retrospective study consists of 987 National Comprehensive Cancer Network low risk, favorable intermediate risk, and unfavorable intermediate risk PCa patient subgroups; GM (173) and USM (814). Differences in baseline covariates and clinical characteristics between GM and USM were analyzed using χ(2) and Mann-Whitney test while Cox Proportional Hazards model was used to assess freedom from biochemical failure differences between the study groups. RESULTS: Median follow-up for this study was 40 months. GM were diagnosed at a younger median age (64 vs. 68 y, P<0.001) with heavier unfavorable intermediate risk disease burden (32.4% vs. 19.2%) compared with USM. Significant differences were identified in median external beam radiotherapy dose (72.4 vs. 78 Gy, P<0.001); brachytherapy utilization (49.7% vs. 80.6%, P<0.001) and androgen deprivation therapy for intermediate risk disease (48.4% vs. 21.0%, P<0.001) between GM and USM, respectively. GM with low risk and favorable intermediate risk PCa were at increased risk of biochemical recurrence compared with USM with adjusted hazard ratio: 5.15 (1.27 to 20.7), P=0.02 and 4.64 (1.20 to 17.92), P=0.02, respectively. CONCLUSIONS: Compared with USM, GM with low and favorable intermediate risk PCa may experience less durable disease control following standard treatment recommendations. Results suggest differences in radiation treatment and possible inherent differences between the 2 populations. This data will aid in developing research strategies to improve treatment outcomes in GM. Lippincott Williams & Wilkins 2019-12 2019-10-03 /pmc/articles/PMC6887629/ /pubmed/31584456 http://dx.doi.org/10.1097/COC.0000000000000589 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Articles: Genitourinary Asamoah, Francis A. Yarney, Joel Awasthi, Shivanshu Vanderpuye, Verna Dadzie, Mary A. Fink, Angelina Naghavi, Arash O. Abrahams, Afua Mensah, James E. Sasu, Evans Tagoe, Samuel N. Dhillon, Jasreman Johnstone, Peter A.S. Yamoah, Kosj Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study |
title | Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study |
title_full | Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study |
title_fullStr | Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study |
title_full_unstemmed | Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study |
title_short | Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study |
title_sort | definitive radiation treatment patterns and outcomes for low and intermediate risk prostate cancer patients: a cross-continental comparative study |
topic | Original Articles: Genitourinary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887629/ https://www.ncbi.nlm.nih.gov/pubmed/31584456 http://dx.doi.org/10.1097/COC.0000000000000589 |
work_keys_str_mv | AT asamoahfrancisa definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT yarneyjoel definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT awasthishivanshu definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT vanderpuyeverna definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT dadziemarya definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT finkangelina definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT naghaviarasho definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT abrahamsafua definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT mensahjamese definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT sasuevans definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT tagoesamueln definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT dhillonjasreman definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT johnstonepeteras definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy AT yamoahkosj definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy |